AARTIDRUGS - Aarti Drugs Limited Share Price

Management's outlook for Aarti Drugs Limited is cautiously optimistic, focusing on recovery and growth in the upcoming quarters. Key forward-looking points discussed include:

1. Capacity Ramp-Up: The Sayakha facility, which commenced operations in September 2025, is expected to reach around 50% utilization by March-April 2026 and aims for 80%-90% utilization within a year.

2. Growth Projections: Management anticipates a volume growth of 12%-15% for FY '27, primarily driven by new projects, particularly in salicylic acid and methyl amines.

3. Profitability Improvement: EBITDA margins are expected to recover, with an initial target of 12%-13%, ultimately aiming for steady-state margins between 14%-15%. Cost savings from backward integration projects could add a couple of percentage points to gross contribution at full capacity, with an estimated boost in EBITDA potential exceeding INR 50 crores.

4. Export Markets: A stronger focus on the export market, particularly for formulations, is anticipated to contribute positively to margins. Exports already accounted for 37% of standalone revenue in Q3 FY '26.

5. Regulatory Approvals: Management is actively pursuing EU GMP certification and U.S. FDA approval for products, which is expected to enhance revenue from regulated markets.

6. Investment Plans: Future capex of INR 150 to 200 crores per year is planned for the next two years, with significant investments in oncology development, capacity expansions, and energy-efficient projects.

7. Market Recovery: Despite challenges such as low antibiotic demand and issues with supply chains, January's sales suggest an encouraging trend providing confidence in improved performance moving forward.

Overall, management's strategy is centered on enhancing operational efficiencies, scaling up production, and maintaining a diversified product portfolio to mitigate market fluctuations and ensure sustainable growth.

Q1: "On the formulation business, is the primary intention to do all formulations of the existing APIs or also other formulations?"
A: I clarified that we're currently working on formulations of APIs manufactured in-house, but we're not limiting ourselves to only those. We're also focusing on niche categories in oncology and cardio-diabetic segments, allowing for broader development opportunities.

Q2: "Regarding metformin, would the backward integration capacities for methylamines be used only for metformin?"
A: I confirmed that the capacities are dedicated to metformin API exclusively, emphasizing our commitment to this segment.

Q3: "Can you quantify the impact of shutdowns and new facilities on this quarter's results?"
A: I estimated the impacted drag at EBITDA level to be roughly INR8 crores, equating to about INR14-15 crores at the PAT level due to delays caused by a voluntary shutdown and lower capacities.

Q4: "What is the current debt on books?"
A: Our total consolidated debt is roughly around INR540 crores, with standalone debt at approximately INR392 crores, evenly split between long-term and short-term obligations.

Q5: "What kind of growth should we expect in FY '27?"
A: We can expect around 12% to 15% volume growth in FY '27, driven primarily by the ramp-up of new projects such as salicylic acid and Sayakha amines, alongside some single-digit growth from existing products.

Q6: "What are the expected EBITDA margins for the next year?"
A: Initially, we aim for EBITDA margins of 12%-13%. Once operations stabilize, we anticipate steady-state margins in the 14%-15% range.

Q7: "Can you share the total investment planned for the oncology business?"
A: The total investment, including capex and product development costs, is projected to be around INR200 crores over the next few years, with annual expenditures for development around INR50-60 crores.

Q8: "How will the recent ban on nimesulide impact revenue?"
A: The ban primarily affects formulations over 100 mg, while we focus on lower dosages. Therefore, our demand in this segment remains unaffected.

Q9: "What capacity utilization are we targeting for the Sayakha plant next year?"
A: We're targeting around 75% utilization for the Sayakha facility in the subsequent quarter after achieving 50% by the end of the current quarter.

Q10: "Is the current Gross Margin trajectory sustainable given the challenges?"
A: Despite challenges, I believe we can achieve around 36% gross margin as salicylic acid plants stabilize, and backward integration projects contribute positively to our gross margins moving forward.